The 2027 RWE Playbook
Most RWE programs weren't built for 2027. They were built for 2019 — before FDA issued device-specific guidance...
Categories
Connect with us on LinkedIn
Trust LLMs with Chart Review: Validation Framework
Most AI chart review vendors oversell accuracy and ignore the pipeline problem entirely. This brief shows what peer-reviewed...
The eCOA Iceberg: uncovering the hidden costs of software-only models
SaaS eCOA looks cheaper on paper. This guide exposes five hidden costs that change the full-service vs. software-only...
The ePRO blueprint for pain trials: Optimizing data capture from protocol design to efficacy endpoints
The 11-point electronic Numeric Rating Scale (eNRS) is now the preferred digital standard for BYOD pain trials, recommended...
Obesity RWD Compliance: The Direct-to-Patient Guide
Over 2,000 active obesity and GLP-1 studies are competing for the same patients. Most still run on traditional...
Own Your Data, Accelerate Your Cure Castor Catalyst — Rare Disease Insight Brief
Rare disease foundations no longer need to wait for pharmaceutical industry interest to develop treatments for their communities....
The real-time monitoring dilemma
Offline eCOA capability creates regulatory tension with EMA device-as-source requirements while eliminating real-time monitoring capabilities that drive 80-95%...
Is Your eCOA UAT Stuck in Time?
Modern clinical trials increasingly rely on complex, time-sensitive logic within eCOA systems, such as narrow compliance windows and...
The End of the “PRO Tax”: Top 10 Commercial PROs & their cost-effective alternatives
The clinical trial industry faces a "PRO Tax"—the high costs and operational delays associated with licensing and implementing...
The Silent Saboteurs: Why Rater Drift and Site Unpreparedness Cost CNS Trials More
CNS trials fail not from technology limitations but organizational factors. Research reveals 55% of sites lack adequate eCOA...
Hospital-Based eCOA Implementation: Real Challenges in Infectious Disease Trials
Hospital-based infectious disease trials face unique eCOA implementation challenges including IT security delays, staff turnover, and patient acuity...
Implications of Assessing Overall Survival in Oncology Studies
The FDA’s August 2025 draft guidance reshapes oncology clinical trials by requiring pre-specified overall survival (OS) analysis in...
The Patient Experience Paradox: eCOA Strategy Overhaul
Discover how the EMA’s new Patient Experience Data (PED) guidance and the EU HTA Regulation are reshaping evidence...
Automated Evidence Generation for Regulatory-Grade Real-World Data
Manual data abstraction can’t keep up with new FDA and EMA RWE standards. This whitepaper explains how automated...
The EMR Interoperability Dream vs. Clinical Research Reality
A Practical Guide to the 21st Century Cures Act, FHIR Data, and Bridging the Gap for Regulatory-Grade Evidence
Discover the real-world challenges of EMR interoperability in clinical research. Learn how the 21st Century Cures Act, FHIR...
ICH GCP E6(R3) Implementation: Practical Approaches and Real-World Considerations
ICH GCP E6(R3) implementation requires strategic planning beyond basic compliance. This practical guide covers realistic 12-18 month timelines,...
Decentralized Clinical Trial Platforms in 2025: A Practical Guide for Clinical Operations
DCT platform evaluation guide: integration strategies, vendor comparison, implementation timelines for clinical operations teams.
Navigating the eCOA Vendor Landscape: What Clinical Teams Really Need to Know
The eCOA market reached $2.27 billion in 2025 with 16.1% projected growth, yet vendor selection remains critical for...